Efficacy of rabies immunoglobulins in an experimental post-exposure prophylaxis rodent model.
In a recently published Syrian hamster animal challenge study [Vaccine 19 (2001) 2273], a highly purified, heat-treated equine rabies immunoglobulin (pERIG HT, Favirab) did not elicit satisfactory protection. The efficacies of this batch, a second stage pERIG HT batch and reference RIG preparations (Imorab, Imogam Rage pasteurised, Berna antiserum) were compared in mice challenged with either Ariana canine field strain or CVS strain. Survival rates against Ariana challenge with the second pERIG HT batch were indistinguishable from those of other licensed preparations (83-90% survival), but the deficient batch did not provide satisfactory protection (53%). These data confirm the inadequate response to a first stage pERIG HT batch, but a current batch provides equivalent protection to that afforded by licensed HRIG and ERIG preparations.
Servat
Alexandre
A
Laboratoire d'études et de recherches sur la rage et la pathologie des animaux sauvages, Agence Française de Sécurité Sanitaire des Aliments (AFSSA), Domaine de Pixérécourt, B.P. 9, Nancy, 54220, Malzéville, France. a.servat@afssa.fr
Lutsch
Charles
C
Delore
Valentine
V
Lang
Jean
J
Veitch
Keith
K
Cliquet
Florence
F
D000818:Animals; D000906:Antibodies / Q000032:analysis; D005260:Female; D006736:Horses / Q000276:immunology; D007116:Immunization, Passive; D051379:Mice; D009500:Neutralization Tests; D011818:Rabies / Q000276:immunology* / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000276:immunology; D011820:Rabies virus / Q000276:immunology; D016019:Survival Analysis; D014611:Vaccination
D000906:Antibodies; D011819:Rabies Vaccines